Recent Updates
Recently added Catalysts
DCTH Positive Sentiment

Delcath Systems Reports Third Quarter 2026 Results and Business Highlights

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Delcath Systems reported strong financial results for Q3 2026, with total revenue reaching $35.1 million, a significant increase from $20.6 million in Q3 2025. The revenue from HEPZATO KIT™ also saw a notable rise, amounting to $32.7 million compared to $19.3 million in the same period last year. These results reflect the company's growth in the interventional oncology market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue increased to $35.1 million.
  • HEPZATO KIT™ revenue rose to $32.7 million.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
26.5%
average across 3 past catalysts
Lead asset
Hepzato Kit (melphalan HDS)
Phase 2 · Refractory Metastatic Colorectal Cancer

Full Press Release Details

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025 HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025

Frequently Asked Questions

What were Delcath Systems' total revenues for Q3 2026?

Total revenues reached $35.1 million in Q3 2026.

How much revenue did HEPZATO KIT™ generate?

HEPZATO KIT™ generated $32.7 million in Q3 2026.

How does Q3 2026 revenue compare to Q3 2025?

Revenue increased from $20.6 million in Q3 2025 to $35.1 million.

What is Delcath Systems focused on?

Delcath Systems focuses on treating primary and metastatic liver cancers.

ShareAdd on Google
Tags: DCTH Delcath Systems HEPZATO KIT interventional oncology liver cancers
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$96M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Hepzato Kit (melphalan HDS)Phase 2
Refractory Metastatic Colorectal Cancer →

Catalyst track record

+45%
best trade around DCTH's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for DCTH.

See every catalyst's timing & PoA →